<DOC>
	<DOC>NCT01081483</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of blinded, single ascending oral doses of ABT 072 under non-fasting conditions in healthy adult Japanese male subjects.</brief_summary>
	<brief_title>A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Overall healthy adult Japanese males Use of any medications (prescription and overthecounter), vitamins, or herbal supplements within the 2week period prior to the first dose of study drug administration or within 10 halflives of the respective medication, whichever is longer. Positive test result for hepatitis A virus immunoglobulin M (HAVIgM), hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or HIV antibodies (HIV Ab). Positive screen for drugs of abuse, alcohol, or cotinine. Clinically significant cardiovascular, respiratory (except mild asthma), renal, gastrointestinal, hematologic, neurologic, thyroid, or any uncontrolled medical illness or psychiatric disorder. Use of tobacco or nicotinecontaining products within the 6month period preceding study drug administration.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>HCV Infections</keyword>
</DOC>